ZURICH (AFX) - Novartis AG said new data from a Phase II study with cancer drug Tasigna shows impressive response rates in leukaemia patients with resistance or intolerance to treatment with Glivec.
According to the data, which forms the basis for US and EU regulatory approvals, Tasigna eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of the adult patients.
The reductions may be the highest ever reported with a targeted therapy at a minimum of six months follow-up, the Basel-based drugs maker said.
source - AFX
